Kolh P, Honore P, Gielen J L, Degauque C, Azzam C, Legrand M, Jacquet N
Department of Surgery, CHU Sart Tilman, Liège, Belgium.
Acta Chir Belg. 1999 May-Jun;99(3):113-8.
We evaluated prognostic factors in 34 patients discharged from hospital after surgical resection for oesophageal squamous cell carcinoma.
There were 22 males and 12 females; mean age was 59.3 years (range 42-77 years). Preoperative neoadjuvant treatment consisted in chemotherapy alone in three patients and in combined radiochemotherapy in 14. Digestive continuity was restored with a gastric transplant in 26 patients and a colonic graft in 8. Surgery was curative in 28 patients and palliative in 6. There were three stage I, 14 stage II, 13 stage III, and 4 stage IV diseases. In 19 patients the lymph nodes were invaded. The tumour was well differentiated in 17 patients, moderately in 9, and poorly in 8.
Follow-up ranged from 2 to 100 months. Overall median postoperative survival was 21 months. By univariate analysis, factors influencing survival were curative surgery (p = 0.04), stage (p = 0.006), and nodal involvement (p = 0.0003). Nodal involvement was an independent prognostic factor by multivariate analysis (p = 0.0002). Patient age and sex, perioperative transfusion, digestive transplant, tumour local extension, grade of differentiation, and distant metastasis did not influence survival. Also, we did not observe any significant benefit of preoperative or postoperative chemotherapy or radiochemotherapy.
Nodal involvement was the most important prognostic factor influencing survival. Therefore, an earlier diagnosis of oesophageal cancer in a less advanced stage is important to improve survival rates. Our study could not confirm the benefit of neoadjuvant therapy in terms of late survival.
我们评估了34例接受手术切除的食管鳞状细胞癌患者出院后的预后因素。
男性22例,女性12例;平均年龄59.3岁(范围42 - 77岁)。3例患者术前新辅助治疗仅为化疗,14例为同步放化疗。26例患者通过胃移植恢复消化道连续性,8例通过结肠移植。28例患者手术为根治性,6例为姑息性。有3例I期、14例II期、13例III期和4例IV期疾病。19例患者有淋巴结侵犯。17例患者肿瘤高分化,9例中分化,8例低分化。
随访时间为2至100个月。总体术后中位生存期为21个月。单因素分析显示,影响生存的因素为根治性手术(p = 0.04)、分期(p = 0.006)和淋巴结受累(p = 0.0003)。多因素分析显示淋巴结受累是独立的预后因素(p = 0.0002)。患者年龄、性别、围手术期输血、消化道移植、肿瘤局部扩展、分化程度和远处转移均不影响生存。此外,我们未观察到术前或术后化疗或放化疗有任何显著益处。
淋巴结受累是影响生存的最重要预后因素。因此,早期诊断处于较早期阶段的食管癌对于提高生存率很重要。我们的研究未能证实新辅助治疗对晚期生存的益处。